A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Atish D ChoudhuryCelestia S HiganoJohann S de BonoNatalie CookDana E RathkopfKari B WisinskiJuan Martin-LiberalMark LinchElisabeth I HeathRichard D BairdJavier García CorbachoMiguel Quintela-FandinoSimon T BarryElza C de BruinSteve ColebrookGeorge HawkinsTeresa KlinowskaBrijesh MarojGanesh MoorthyPeter G S MortimerMichele MoschettaMyria NikolaouLiz SainsburyGeoffrey I ShapiroLillian L SiuAaron Richard HansenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
AZD8186 monotherapy had an acceptable safety and tolerability profile, and combination with abiraterone acetate/prednisone or vistusertib was also tolerated. There was preliminary evidence of antitumor activity, meriting further exploration of AZD8186 in subsequent studies in PI3Kβ pathway-dependent cancers.